These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8378841)

  • 1. [The possible approaches to the theoretical validation of the use of cytostatics and corticosteroids in treating glomerulonephritis].
    Ivanov AA; Shilov EM; Gladskikh OP; Krasnova TN; Karpukhin VV; Gitel' EP; Pal'tsev MA
    Ter Arkh; 1993; 65(6):23-6. PubMed ID: 8378841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of mononuclear leukocytes in the pathogenesis of glomerulonephritis].
    Shilov EM; Gabrilevskaia OV; Ivanov AA; Gladskikh OP; Leskov VP; Pal'tsev MA; Tareeva IE
    Ter Arkh; 1991; 63(6):21-6. PubMed ID: 1948736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy.
    Mustonen J; Pasternack A; Rantala I
    Clin Nephrol; 1983 Oct; 20(4):172-6. PubMed ID: 6641024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of chronic glomerulonephritis with cytostatics].
    Tareeva IE; Gordovskaia NB; Gladskikh OP; Ivanov AA; Krasnova TN
    Ter Arkh; 1989; 61(6):9-14. PubMed ID: 2799726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunosuppressive therapy update 2010 for ANCA-associated glomerulonephritis and intractable nephrotic syndrome].
    Yoshida M
    Nihon Jinzo Gakkai Shi; 2010; 52(1):1-9. PubMed ID: 20166533
    [No Abstract]   [Full Text] [Related]  

  • 6. [Influence of immunosuppressors on remodeling of extracellular matrix in experimental nephropathies].
    Pal'tseva EM; Gladskikh OP; Ivanov AA
    Arkh Patol; 2002; 64(4):31-4. PubMed ID: 12402553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The pharmacotherapy of chronic glomerulonephritis].
    Ratner MIa; Biriukova LS
    Klin Med (Mosk); 1992 Jan; 70(1):114-9. PubMed ID: 1608196
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of treatment with corticosteroids and indomethacin on proteinuria].
    Michielsen P; Lambert PP
    J Urol Nephrol (Paris); 1967; 73(4):340-55. PubMed ID: 6066085
    [No Abstract]   [Full Text] [Related]  

  • 9. [The cyclophosphamide treatment of glomerulonephritis patients].
    Dorets'kyĭ VV
    Vrach Delo; 1991 Feb; (2):51-3. PubMed ID: 2058123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of cyclophosphamide on the length of remission in patients suffering from glomerulonephritis with nephrotic syndrome].
    Duman VL; Shkerina LI; Shilov EM
    Klin Med (Mosk); 2005; 83(10):48-50. PubMed ID: 16320847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of methylprednisolone and cyclophosphamide pulse therapy on renal infiltrating cells in patients with crescentic glomerulonephritis.
    Tang Z; Zhou H; Yao X; Hu W; Leishi L
    Chin Med J (Engl); 1997 Mar; 110(3):206-9. PubMed ID: 9594342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differentiated therapy of nephrotic syndrome in childhood (author's transl)].
    Brodehl J
    Monatsschr Kinderheilkd (1902); 1974 Aug; 122(8):748-55. PubMed ID: 4605623
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful management of idiopathic rapidly progressive glomerulonephritis with corticosteroids and cytotoxic agent.
    Adhikary L; Simkhada R
    Kathmandu Univ Med J (KUMJ); 2005; 3(3):289-91. PubMed ID: 18650595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of corticosteroids in renal disease.
    Lawrence JR
    Drugs; 1974; 8(6):438-47. PubMed ID: 4156322
    [No Abstract]   [Full Text] [Related]  

  • 15. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.
    Reynolds J; Moss J; Duda MA; Smith J; Karkar AM; Macherla V; Shore I; Evans DJ; Woodrow DF; Pusey CD
    J Pathol; 2003 May; 200(1):118-29. PubMed ID: 12692850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New approaches to therapy in glomerulonephritis patients].
    Riabov SI; Rakitianskaia IA; Stavskaia VV; Nikitina NA
    Ter Arkh; 1996; 68(6):24-7. PubMed ID: 8771678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Membranous nephropathy and crescentic glomerulonephritis].
    Vozmediano C; Sánchez de la Nieta MD; González L; Alvarez T; de la Torre M; Blanco J; Nieto J; Rivera F
    Nefrologia; 2005; 25(3):328-31. PubMed ID: 16053015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sandimmun in the treatment of chronic glomerulonephritis with the nephrotic syndrome].
    Krasnova TN; Tareeva IE; Shilov EM; Mukhin NA; Miroshnichenko NG
    Ter Arkh; 1997; 69(6):21-3. PubMed ID: 9297266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Immunosuppression in nephrotics--praises and restraints.
    Chugh KS
    J Assoc Physicians India; 1973 Jan; 21(1):77-9. PubMed ID: 4792705
    [No Abstract]   [Full Text] [Related]  

  • 20. Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.
    Phoon RK; Kitching AR; Jones LK; Holdsworth SR
    Nephrology (Carlton); 2009 Oct; 14(7):650-7. PubMed ID: 19796023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.